Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

Studies show that if you have diabetes, increasing your Time in Range (TIR) can lower your risk of developing kidney disease. Learn how kidney disease is diagnosed, why A1C has limitations for people with CKD, and the link between your TIR and your risk for kidney disease. Continue Reading »

A recent consensus report from leading experts details a new definition for what it means to have type 2 diabetes in remission and why it is important to use the proper terminology in place of other words, such as “reversal” or “cure.” Continue Reading »

Kerendia (also known as finerenone) can reduce the risk of heart attacks, hospitalization for heart failure, and cardiovascular death for adults with chronic kidney disease in people with type 2 diabetes. Continue Reading »

The number of youths being diagnosed with type 2 diabetes each year is on the rise. Learn about the early signs of type 2 diabetes in children and adolescents, the latest approved treatments, methods of prevention, and much more. Continue Reading »

Jardiance (empagliflozin), an SGLT-2 inhibitor, was approved by the FDA to help adults who have heart failure with reduced ejection fraction (HFrEF). Results from EMPEROR-Preserved also show Jardiance benefits those with heart failure with preserved ejection fraction (HFpEF). The FDA has now approved Jardiance for all people with heart failure regardless of diabetes status. Continue Reading »

At the ADCES 2021 conference three diabetes care and education specialists gave their recommendations for how to craft an individual exercise routine and how to avoid common pitfalls. Continue Reading »

Curious to know what apps are available to you to help you manage a variety of health conditions? At the ADCES 2021 conference, experts discussed the best options out there from diabetes prevention to weight management to exercise and more. Continue Reading »

A survey jointly conducted by diabetes research company dQ&A and The diaTribe Foundation assessed how well endocrinologists understood Time in Range and which diabetes metrics they consider most important for setting treatment goals. Continue Reading »

Pages